NJ slams FDA on conflicts of interest

By Nick Taylor

- Last updated on GMT

Related tags: Clinical trial, Food and drug administration

New Jersey’s attorney general has called on the FDA to stop the “rampant undisclosed financial conflicts of interest” in clinical trials.

Anne Milgram, New Jersey’s attorney general, appealed to the US Food and Drug Administration (FDA) after settling a case with Synthes, which gained pre-market approval from the agency “even when the financial conflict disclosures were plainly inadequate​”.

The settlement with Synthes requires the company to ​disclose any future payments to, or company stock held by, physicians conducting its clinical trials.

In addition the company must pay physicians “fair market value compensation​”, which cannot be done in company shares, and disclose all financial interests directly to health care facilities serving as clinical trial sites.

This has been hailed by Milgram as a template for the entire industry, which would stop the practices that, in the NJ’s attorney general’s opinion, is “simply wrong”.

Milgram added: “It is outrageous that doctors who are testing and, in many cases, recommending the use of certain high-risk medical devices are being compensated with stock in the very companies that make the devices.

All patients – but especially those considering high-risk devices such as spinal disc replacements -- deserve honest, objective clinical trial information about the products available.We cannot allow financial conflicts of-interest to infect the clinical trial process. It is a betrayal of the public trust, and has the potential to jeopardise patient well-being.”

“FDA did nothing to regulate these conflicts”

The State of New Jersey launched an investigation into the financial conflicts of interests of the investigators participating in the clinical trials for Synthes in February 2008.

During the investigation it was revealed that the majority of physicians working on the clinical trial had significant investments in the product being tested, which would be worthless if it failed to gain regulatory approval.

Synthes failed to adequately disclose these conflicts of interest, which Milgram believes “should have been obvious from even a cursory review of its FDA submissions​”.

Consequently Milgram has written to Joshua Sharfstein, then acting commissioner at the FDA, calling on the agency to adopt the agreement with Synthes as part of “best practices​” for the industry.

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 01-Nov-2021 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Automating clinical trials for success

Automating clinical trials for success

Formedix | 06-Oct-2021 | Technical / White Paper

This article gives gives a brief overview of why automation is absolutely essential for clinical trial success.

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Related suppliers

Follow us


View more